Surgery – Miscellaneous – Methods
Patent
1999-12-21
2000-12-05
Nguyen, Dinh X.
Surgery
Miscellaneous
Methods
A61B 1900
Patent
active
061552666
ABSTRACT:
Method for treatment of cancer and infectious disease comprises administering a first composition containing interferon-.alpha. or analogues thereof, together with a second composition containing at least one substance with H.sub.2, or 5-HT.sub.1A, receptor agonist activity, for example, histamine or serotonin. The first and second compositions are either mixed in a preparation or furnished in separate doses.
REFERENCES:
patent: 4863727 (1989-09-01), Zimmerman et al.
patent: 4883661 (1989-11-01), Daly et al.
patent: 4997645 (1991-03-01), Suzuki et al.
patent: 5026544 (1991-06-01), Albrecht et al.
patent: 5215744 (1993-06-01), Suzuki et al.
Burtin et al., "The Influence of Intraperitoneal Injections of Histamine on Tumour Growth in Fibrosarcoma-Bearing Mice", Cancer Letters, 12: 195-201, Jan. 1981.
Osband et al., "Successful Tumour Immumotherapy with Cimetidine in Mice", The Lancet, No. 8221, 1: 636-638, Mar. 21, 1981.
Seaman et al., "Suppression of Natural Killing in Vitro by Monocytes and Polymorphonuclear Leukoctues", The Journal of Clinical Investigation, 69: 876-888, Apr. 1982.
Dempsey et al., "The Differential Effects of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor, T Cell Growth Factor, and Interferon on Human on Human Natural Killer Activity", The Journal of Immunology, May 17, 1982.
Barna et al. "Tumor-Enhancing of Cimetidine". Oncology, 40: 43-45, 1983.
Thornes et al., "Combination of Cimetidine with other Drugs for Treatment of Cancer", New England Journal of Medicine, 308: 591-592, Mar. 10, 1983.
Beer et al., "The Influence of Histamine on Immune and Inflammatory Responses", Advances in Immunology, 35: 209-268, 1984.
Lespinatas et al., "Enhancement by serotonin of intra-tumour penetration of spleen cells", Br. J. Cancer, 50: 545-547, Apr. 5, 1984.
Dohlsten et al., "Histamine Inhibits Interferon-.gamma. Production via Suppression of Interleukin 2 Synthesis", Cellular Immunology, 101: 493-501, 1986.
Nair et al., "Histamine-Induced Suppressor Factor Inhibition of NK Cells: Reversal with Interferon and Interleukin 2", The Journal of Immunology, 136(7): 2456-2462, Apr. 1, 1986.
Hellstrand et al., "Histamine H.sub.2 -Receptor-Mediated Regulation of Human Natural Killer Cell Activity", The Journal of Immunology, 137(2), Jul. 15, 1986.
Hellstrand, "Biogenic Amine in the Regulation of Human Natural Killer Cell Cytotoxicity" Published by Medi Press Research Reports, Printed by Novem Grafiska AB, Goteborg 1987.
Hellstrand et al., "Differential Effects of Histamine Receptor Antagonists on Human Natural Killer Activity", Int. Archs Allergy Appl. Immunology 84: 247-255, 1987.
Richtsmeier et al., "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer", Ann. Otol. Rhinol. Laryngol., 96(5):569-572, 1987.
Burtin et al., "Clinical Improvement in Advanced Cancer Disease After Treatment Combining Histamine and H.sub.2 -Antihistamatics (Ranitidine or Cimetidine)" Accepted Jun. 1987.
Hellstrand et al., "Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity", The Journal of Immunology, 139(3), Aug. 1, 1987.
Urba et al., "Enhancement of Natural Killer Activity in Human Peripheral Blood by Flavone Acetic Acid", The Journal of the National Cancer Institute, 80(7): 521-525, Jun. 1, 1988.
Hornung et al., "Augmentation of Natural Killer Activity, Induction of IFN and Development Tumor Immunity During the Successful Treatment of Established Murine Renal Cancer Using Flavone Acetic Acid and IL-2", The Journal of Immunology, 141(10): 3671-3679, Nov. 15, 1988.
Ostensen et al., "Enhancement of Human Natural Killer Cell Function by the Combined Effects of Tumor Necrosis Factor .alpha. or Interleukin-1 and Interferon-.alpha. or Interleukin-2", Journal of Biological Response Modifiers, 8: 53-61, 1989.
Hellstrand et al., "Suppression of human natural killer cell cytotoxicity by interleukin-2", Clin. Exp. Immunol., 77: 410-416, 1989.
Alam et al., "Comparative Effect of Recombinant IL-1,-2,-3,-4, and -6, IFN-.gamma., Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor-.alpha., and Histamine-Releasing Factors on the Secretion of Histamine from Basophils", The Journal of Immunology, 142(10): 3431-3435, May 18, 1989.
Schleimer et al., "Regulation of Human Basophil Mediator Release by Cytokines", The Journal of Immunology, 143(4): 1310-1317, Aug. 15, 1989.
Hellstrand et al., "A Cell-to-Cell Mediated Interaction Involving Monocytes and Non T/CD16.sup.+ Natural Killer (NK) Cells is Required for Histamine H.sub.2 -Receptor-Mediated NK-Cell Activation", Scand. J. Immunol., 31: 631-644, 1990.
Hellstrand et al., "Enhancement of Human Natural Killer Cell Cytotoxicity by Serotonin: Role of Non-T/CD176.sup.+ NK Cells, Accessory Monocytes, and 5-HT 1A Receptors", Cellular Immunology, 127: 199-214, 1990.
Hellstrand et al., "Monocyte-Mediated Suppression of IL-2-Induced NK-Cell Activation", Scand. J. Immunol. 32: 183-192, 1990.
Hellstrand et al., "Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and Interleukin-2", Int. Arch. Allergy Appl. Immunotherapy, 92: 379-389, 1990.
Tom Smith, MD, "Histamine Type 2-Receptor Antagonists and Cancer Immunotherapy", Comprehensive Therapy, 16(1): 8-13, 1990.
Krigel et al., "Renal Cell Carcinoma: Treatment with Recombinant Interleukin-2 Plus Beta-Interferon", Journal of Clinical Oncology, 8(3): 460-467, Mar. 1990.
Hellstrand et al., Role of Histamine in Natural Killer Cell-Mediated Resistance Against Tumor Cells:, The Journal of Immunology, 145(12), Dec. 15, 1990.
Hellstrand et al., "Cell-to-Cell Mediated Inhibition of Natural Killer Cell Proliferation by Monocytes and its Regulation by Histamine H.sub.2 -Receptors", Scand. J. Immunol., 34: 741-752, 1991.
Hellstrand et al., "Monocyte-Induced Down-Modulation of CD16 and CD56 Antigens on Human Natural Killer Cells and its Regulation by Histamine H.sub.2 -Receptors", Cellular Immunology, 138: 44-45, 1991.
Schantz et al., "A phase II study of interleukin-2 and interferon-alpha in head and neck cancer", Investigation New Drugs, 10: 217-223, 1992.
Hellstrand et al., "Regulation of Natural Killer Cell Response to Interferon-.alpha. by Biogenic Amines", Journal of Interferon Research, 12: 199-205, 1992.
Budd et al., "Phase I Trial of High-Dose Bolous Interleukon-2 and Interferon Alfa-2 in Patients with Metastatic Malignacy", Journal of Clinical Oncology 10(5): 804-809, May 1992.
IIson et al., "A Phase II Trial of Interleukin-2 and Interferon Alfa-2a in Patients with Advanced Renal Cell Carcinoma" Journal of Clinical Onocology, 10(7): 1124-1130, Jul. 1992.
Saarloos et al., "Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis" Clin. Exp. Metastasis, 11: 275-283, 1993.
Hellstrand et al., "Serotonergic 5-HT.sub.1A Receptors Regulate a Cell Contact-Mediated Interaction between Natural Killer Cells and Monocytes", Scand. J. Immunol., 37: 7-18, 1993.
Hellstrand et al., "Histamine in Immunotherapy of advanced melanoma: a pilot study", Cancer Immunol. Immunother, 39: 416-419, 1994.
Chun, Myung et al., "Modulation of Interferon-Induced NK Cells by Interleukin 2 and cAMP", Lymphokine Research, 1(4): 91-98, 1982. Abstract only.
Hellstrand Kristoffer
Hermodsson Svante
Maxim Pharmaceuticals, Inc.
Nguyen Dinh X.
LandOfFree
Method for treatment of cancer and infectious disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of cancer and infectious disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of cancer and infectious disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-951847